English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, March 8, 2023
亿胜生物公布2022年度业绩
億勝生物公布2022年度業績
Essex Bio-Technology Announces 2022 Annual Financial Results
Wednesday, February 22, 2023
亿胜生物与复宏汉霖签订治疗年龄相关性黄斑变性全球共同开发及独家许可协议之经修订协议
億勝生物與復宏漢霖簽訂治療年齡相關性黃斑變性全球共同開發及獨家許可協議之經修訂協議
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration
Friday, February 10, 2023
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases
亿胜生物宣布贝伐珠单抗眼科适应症国际多中心III期临床研究完成美国首例患者给药
億勝生物宣佈貝伐珠單抗眼科適應症國際多中心III期臨床研究完成美國首例患者給藥
Thursday, October 13, 2022
Essex Biotechnology Secures Exclusive Rights and Interests in SkQ1 for Ophthalmology from Mitotech

Copyright © 2023 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575